IKAP Stock Overview
A commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for IKAP from our risk checks.
Aurinia Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.23 |
| 52 Week High | US$8.57 |
| 52 Week Low | US$4.36 |
| Beta | 1.46 |
| 11 Month Change | 29.92% |
| 3 Month Change | 39.15% |
| 1 Year Change | -0.58% |
| 33 Year Change | -51.75% |
| 5 Year Change | 21.96% |
| Change since IPO | 33.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| IKAP | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.1% | 0.8% | -1.3% |
| 1Y | -0.6% | -17.5% | 7.4% |
Return vs Industry: IKAP exceeded the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: IKAP underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| IKAP volatility | |
|---|---|
| IKAP Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: IKAP has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: IKAP's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 300 | Peter Greenleaf | www.auriniapharma.com |
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd.
Aurinia Pharmaceuticals Inc. Fundamentals Summary
| IKAP fundamental statistics | |
|---|---|
| Market cap | €1.20b |
| Earnings (TTM) | -€21.55m |
| Revenue (TTM) | €210.58m |
5.7x
P/S Ratio-55.7x
P/E RatioIs IKAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IKAP income statement (TTM) | |
|---|---|
| Revenue | US$220.36m |
| Cost of Revenue | US$51.00m |
| Gross Profit | US$169.36m |
| Other Expenses | US$191.92m |
| Earnings | -US$22.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 76.86% |
| Net Profit Margin | -10.23% |
| Debt/Equity Ratio | 0% |
How did IKAP perform over the long term?
See historical performance and comparison